Target intelligence / Profile preview

Membrane integral NOTCH2-associated receptor 2 (MINAR2)

Target
MINAR2
Molecular classification
Receptor, Intrinsically disordered protein, Membrane protein
01

Overview

Membrane integral NOTCH2-associated receptor 2 (MINAR2) is a membrane protein essential for normal hearing in humans and mice, encoded by the MINAR2 gene[1][2]. MINAR2 is highly expressed in the cochlear hair cells, spiral ganglia, spiral limbus, and stria vascularis of the inner ear, where it supports proper auditory function without being required for hair cell survival during early development. Loss-of-function variants in MINAR2 cause autosomal recessive, nonsyndromic sensorineural hearing loss due to progressive disruption of cochlear hair cell synapses and stereocilia organization. Mechanistically, MINAR2 acts as a negative regulator of NOTCH2 signaling, downregulates VEGFA, and inhibits mTOR and MAP kinase pathways. No drugs are currently known to target MINAR2, but its restricted function and preserved hair cells in mutant animals make it a candidate for genetic therapies for hereditary deafness[1][2].

Other names
Major intrinsically disordered NOTCH2-binding receptor 1-likeMINAR2KIAA1024LDFNB120UPF0258 protein KIAA1024-likeMembrane integral NOTCH2 associated receptor 2Major intrinsically disordered NOTCH2-associated receptor 2Major intrinsically disordered Notch2-binding receptor 1-like
02

Mechanism of action

No drugs targeting MINAR2 are currently described; mechanistic studies suggest its activity involves suppression of NOTCH2, VEGF, mTOR, and MAP kinase (ERK1/2) pathways[1][2].

03

Biological functions

Maintenance of cochlear hair cell functionRegulation of synapse maintenance in inner earSuppression of NOTCH2 abundance (negative regulator of NOTCH2 signaling)Inhibition of mTOR (mammalian target of rapamycin) signaling pathwayModulation of MAP kinase/ERK signalingPotential involvement in angiogenesis via VEGF/NOTCH interactions
04

Disease associations

Sensorineural hearing loss (early-onset, autosomal recessive nonsyndromic deafness)Potential involvement in neurodevelopment via effect on synaptic maintenance
05

Safety considerations

Not applicable; no therapies targeting MINAR2 are in clinical use or have reported toxicities.
06

Interacting drugs

None known
07

Biomarkers

MINAR2 gene mutations serve as biomarkers for congenital and prelingual severe-to-profound sensorineural hearing loss[1][2].

Beyond the preview

Go deeper on Membrane integral NOTCH2-associated receptor 2 (MINAR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Membrane integral NOTCH2-associated receptor 2 (MINAR2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call